3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Muscle Invasive Bladder Cancer
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumours
1
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
1
Advanced Solid Malignancies
1
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Muscle Invasive Bladder Cancer
×
danvatirsen
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled